

Post-acute health care utilization after SARS-CoV-2 infection: A retrospective cohort study of long COVID among 530,892 adults

Supplemental Materials

Figure E1. Cohort Construction

Figure E2: Among individuals at the 95th percentile of health care utilization, additional health care encounters (95% CI) per person-year total and by type of health care encounter, comparing individuals with a positive SARS-CoV-2 PCR test to matched individuals with negative PCR: (A) overall (n=530,232), (B) women (n=271,346), and (C) men (n=258,886).

Table E1. ICES Databases

Table E2. Variables included in the propensity score for matching

Table E3. Unmatched cohort baseline characteristics

Table E4. Distribution of baseline healthcare use by counts and rates (per person-year) for the matched cohort (n= 530,232), overall and stratified by sex.

Table E5: Sensitivity analyses: (A) Follow-up begins after hospital discharge or 56 days, whichever occurred later, (B) follow-up censored on the date of entrance to long-term care, (C) follow-up censored at 6 months, and (D) matched by intensive care admission within two weeks after index date. All comparisons are for test-positive versus test-negative individuals. Distribution of follow-up time included for each analysis. Healthcare utilization rates reported per person-year. The difference in overall healthcare utilization rates between test-positive and negative individuals are reported for the mean, 95th percentile, and 99th percentile. Samples sizes as noted below.

Figure E1: Cohort construction






Figure E2: Among individuals at the 95th percentile of health care utilization, additional health care encounters (95% CI) per person-year total and by type of health care encounter, comparing individuals with a positive SARS-CoV-2 PCR test to matched individuals with negative PCR: (A) overall (n=530,232), (B) women (n=271,346), and (C) men (n=258,886).

(A) Overall (n=530,232)



(B) Women (n=271,346)



(C) Men (n=258,886)




Table E1. ICES Databases

The following datasets were used for cohort construction, among others (Table E1): OHIP (contains all physician billing claims); the Registered Persons Database (maintains vital statistics, including out-of-hospital deaths); the Ontario Laboratories Information System (contains all PCR results for SARS-CoV-2 and was linked to the COVID19 database, which records all SARS-CoV-2 vaccinations); the Canadian Institute for Health Information Discharge Abstract Database (records all hospitalizations in Ontario); the National Ambulatory Care Reporting System (includes all emergency department visits in Ontario); and the Ministry of Health and Long-Term Care (MOHLTC; residence in long-term care).

CIHI	NRS	HCD	CENSUS	INST	ODD
OHIP	ODB	RAICA	LIHN	ASTHMA	DEMENTIA
NACRS	CCRS	IPDB	REF	HYPER	COPD
SDS	CONTACT	CPDP	PCCF	HIV	ORAD
OHMRS	RAIHC	RPDB	DIN	CHF	OCCC
ODD	CCN	OCR	CDFP	ADP	ERCLAIM
AVGPRICE	ORGD	ETHNIC	Getacg	ESTSOB	GAPP
ONMARG	CCM	C19INTGR	DAD	COVAXON	OLIS
CAPE	NMS	OCCI	OHCAS		

Table E2. Variables included in the propensity score for matching*

* also used for hard matching

Variable	Definition and/or source
Sex*	Male, female
Week of outbreak*	Index date January 28, 2020; two-week blocks
Hospitalization*	On or within 2 weeks after the index date
Public health unit (PHU)*	OMHRS, DAD
Age	Years, restricted cubic spline
Neighbourhood income quintile	RPDB, PCCF
Residential instability	ONMARG quintiles
Material deprivation	ONMARG quintiles
Dependency	ONMARG quintiles
Ethnic concentration	ONMARG quintiles
Rurality	RPDB, PCCF
Week of outbreak	Index date January 28, 2020; two-week blocks
Diabetes	ODD_sensitive
Pregnancy	MOMBABY ¹⁻⁴
Hypertension	HYPER
Acute myocardial infarction	≥1 DAD ICD10: I21, I22, I25.2
Percutaneous coronary intervention	CIHI DAD/SDS: CCP: 48.02, 48.09; CCI: 1IJ50, 1IJ57GQ 1IJ80, 1IJ26, 1IJ54, 1IJ55; OHIP: Z434, Z448, Z449, Z460, Z461
Coronary artery bypass surgery	(CIHI DAD/SDS): CCI 1IJ76; CCP 48.1, 48.2; OHIP R742, R743
Ischemic stroke	One DAD, 2 OHIP, or 1 NACRS&1OHIP: ICD-10 codes I63, I64, H341 (excluding I63.6) as ANY diagnosis type, exclude suspect; ICD-9 code 434, 436 for OHIP
Hemorrhagic stroke	1 record in DAD or NACRS: ICD-10 I60, I61; ICD-9 430, 431
Major bleeding event	ICD 10: GI: I850, I983, K250/252/254/256, K260/262/264/266, K270/272/274/276, K280/282/284/286, K290, K661, K920, K921, K922 ICH: I60, I61, I620, I621, I629 GU: N020-029, R310, R311, R318 Resp: R040, R041, R042, R048, R049 Other: R58, D68.3, H35.6, H45.0, M25.0

Solid cancer, hematologic cancer	OCR: OCR_TOPOG_CD, OCR_DIAG_DATE	
Same-day surgery in prior 6 weeks	SDS_ADMDATE, SDS_INCODE1-10, SDS_CACSANETECH	
Valvular disease	ICD9: 394, 395, 396 ICD10: I019, I020, I05, I08, I099, I342, I348, I349 ICD10 code Z952, and CCI codes 1HS90LACF, 1HT90LACF, 1HU90DACF, 1HU90LACF, 1HU90PNCF, 1HV90LACF, 1HV90LACFA, 1HV90LACFL, 1HV90LACFN, 1HV90WJCFN	
Emphysema	COPD_SPECIFIC in COPD database	
Asthma	ASTHMA_SPEC in ASTHMA database	
Atrial fibrillation	Any of the following: -history of hospitalization (CIHI DAD) ⁵ : ICD9 427.3 or ICD10 I48 as any diagnosis type, including suspected -history of ED visit with same codes -4 OHIP claims in 1 year (OHIP) <i>dxcode</i> 427	
Heart failure	CHF database	
Ischemic heart disease	PCI, CABG, (1 HOSP in DAD with any codes I20-I25) or (2 OHIP billings within a one-year period with dx codes 410-414)	
Renal disease	DAD code: ICD10 codes E102, E112, E132, E142, I12, I13, N01.*, N03.*, N05.*, N08.*, N18.*, N19.*, N25.* or Chronic Dialysis (Any 2 codes within 90 days of one another): OHIP: R849, R850, G323, G325, G326, G330, G331, G860, G333, G083, G091, G085, G295, G082, G090, G092, G093, G094, G861, G862, G863, G864, G865, G866, G294, G095, G096 CCP: 51.95, 66.98 NACRS: CCI: 1PZ21HQBR, 1PZ21HPD4	
Pneumonia	(CIHI DAD, NACRS, OHIP) – ICD-10 codes J10.0, J11.0 or J12-J18 as ANY diagnosis type, exclude suspected ⁶ ; OHIP <i>dxcode</i> 486, excluding claims associated with fee codes G538, G539, G840-G848, G590, G591 or G700 (administration of vaccinations)	
Dementia	(1 DAD or 3 OHIP billings separated by 30 days, within a 2-year period or any cholinesterase inhibitor from ODB) ICD10 codes F00-F03, F051, G30, G31, R54 ICD9 code 290, 294, 331, 797 SUBCLNAM= CHOLINESTERASE INHIBITORS ODB: donepezil, galantamine, or rivastigmine (DIN: 02232043, 02232044, 02269457, 02269465, 02244298, 02244299, 02244300, 02244302, 02266717, 02266725) or Tacrine (Cognex) (DIN: 66123288, 66123290, 66123306, 66123318)	
Alcohol substance use disorder	ICD10 codes F1094, F1029, F1019, F1099, F10250, F10150, F10950, F10920, F10929, F10251, F10251, F10151, F10951, F1027, F1097, F1026, F1096, F10129, F10120, F1010, F1021, F1020, F10220, F10229 ICD9 codes 291, 303	
Johns Hopkins ACG score	Sum of ADGs (from OHIP, NACRS-ED, CIHI DAD)	
John Hopkins frailty indicator	(OHIP, NACRS-ED CIHI DAD)	
Influenza vaccination	2019-20 influenza vaccination (OHIP, ODB) – Received between Sep 1, 2019 and COVID test date. Use algorithm in Concept Dictionary and attached MOHLTC bulletin (pdf) for publically funded DINs for 2019-20 season. Note: algorithm does not capture vaccinations received outside doctor's offices and pharmacies	
Venous thromboembolism	CIHI-NACRS, DAD, OHIP	
	ICD-10 Code	Description
		DX10CODE1 in NACRS, DX10CODE1-10 in DAD
	I26.*	Pulmonary embolism
	I26.0	Pulmonary embolism with mention of acute cor pulmonale
	I26.9	Pulmonary embolism without mention of acute cor pulmonale
	I80.*	Phlebitis and thrombophlebitis [†]
	I80.1	Phlebitis and thrombophlebitis of femoral vein
	I80.2	Phlebitis and thrombophlebitis of other deep vessels of

		lower extremities - Deep vein thrombosis NOS
	I80.3	Phlebitis and thrombophlebitis of lower extremities, unspecified - Embolism or thrombosis of lower extremity NOS
	I80.8:	Phlebitis and thrombophlebitis of other sites;
	I80.9:	Phlebitis and thrombophlebitis of unspecified site
	I82.*	Other venous embolism and thrombosis†
	I82.2	Embolism and thrombosis of vena cava
	I82.8	Embolism and thrombosis of other specified veins
	I82.9	Embolism and thrombosis of unspecified vein -Embolism of vein NOS -Thrombosis of vein NOS
	OHIP DXCODE	Description
	415	Pulmonary embolism, pulmonary infarction
	451	Phlebitis, thrombophlebitis
	452	Portal vein thrombosis
	453	Other venous embolism and thrombosis
	†Excludes: I80.0: Phlebitis and thrombophlebitis of superficial vessels of lower extremities ‡Excludes: I82.0: Budd-Chiari syndrome, I82.1: thrombophlebitis migrans. I82.3: Embolism and thrombosis of renal vein	
Mental health inpatient stay	NACRS	
Mental health ED visit	OHIP ⁷⁻⁹	
MHA Outpatient Services	OHIP ⁷⁻⁹	
Outpatient clinical encounters in previous year	OHIP	
ED visits in previous year	DAD, NACRS	
Same-day surgery in previous year	SDS_ADMDATE, SDS_INCODE1-10, SDS_CACSANETECH	
Days hospitalized in previous year	DAD	
Homecare encounters in previous year	HCD	

Supplemental Material References

1. Aoyama K, Ray JG, Pinto R, et al. Temporal Variations in Incidence and Outcomes of Critical Illness Among Pregnant and Postpartum Women in Canada: A Population-Based Observational Study. *J Obstet Gynaecol Can.* 2019;41(5):631-640.
2. Metcalfe A, Lix LM, Johnson JA, et al. Validation of an obstetric comorbidity index in an external population. *BJOG.* 2015;122(13):1748-1755.
3. Joseph KS, Fahey J, Canadian Perinatal Surveillance S. Validation of perinatal data in the Discharge Abstract Database of the Canadian Institute for Health Information. *Chronic Dis Can.* 2009;29(3):96-100.
4. Samiedaluie S, Peterson S, Brant R, Kaczorowski J, Norman WV. Validating abortion procedure coding in Canadian administrative databases. *BMC Health Serv Res.* 2016;16:255.
5. Tu K, Nieuwlaat R, Cheng SY, et al. Identifying Patients With Atrial Fibrillation in Administrative Data. *Can J Cardiol.* 2016;32(12):1561-1565.
6. Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. *N Engl J Med.* 2013;369(2):155-163.
7. MHASEF Research Team. Mental Health and Addictions System Performance in Ontario: A Baseline Scorecard. Toronto, ON: Institute for Clinical Evaluative Sciences; 2018. Available from: <https://www.ices.on.ca/Publications/Atlases-and-Reports/2018/MHASEF>.
8. MHASEF Research Team. The Mental Health of Children and Youth in Ontario: 2017 Scorecard. Toronto, ON: Institute for Clinical Evaluative Sciences; 2017. ISBN: 978-1-926850-72-6. Available

- from: <https://www.ices.on.ca/Publications/Atlases-and-Reports/2017/MHASEF>.
9. ICES Data Dictionary.
<https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx>.
Last accessed February 11, 2022.

Table E3: Unmatched cohort, baseline characteristics

		Negative SARS-CoV-2 PCR	Positive SARS-CoV-2 PCR	Total	Standardized Difference
VARIABLE		N=3,362,519	N=268,521	N=3,631,040	
Age, years	Mean \pm SD	46.77 \pm 18.17	44.18 \pm 17.18	46.58 \pm 18.11	0.15
	Median (IQR)	45 (31-60)	43 (29-56)	45 (31-60)	0.14
Women, n (%)		1,864,241 (55.4%)	137,245 (51.1%)	2,001,486 (55.1%)	0.09
Income Quintile, n (%)	Missing	10,050 (0.3%)	774 (0.3%)	10,824 (0.3%)	0
	1	630,532 (18.8%)	66,584 (24.8%)	697,116 (19.2%)	0.15
	2	649,204 (19.3%)	58,115 (21.6%)	707,319 (19.5%)	0.06
	3	672,162 (20.0%)	57,233 (21.3%)	729,395 (20.1%)	0.03
	4	684,228 (20.3%)	47,450 (17.7%)	731,678 (20.2%)	0.07
	5	716,343 (21.3%)	38,365 (14.3%)	754,708 (20.8%)	0.18
Instability Quintile, n (%)	Missing	37,365 (1.1%)	2,063 (0.8%)	39,428 (1.1%)	0.04
	1	691,223 (20.6%)	72,327 (26.9%)	763,550 (21.0%)	0.15
	2	626,597 (18.6%)	44,606 (16.6%)	671,203 (18.5%)	0.05
	3	610,179 (18.1%)	40,798 (15.2%)	650,977 (17.9%)	0.08
	4	610,967 (18.2%)	43,693 (16.3%)	654,660 (18.0%)	0.05
	5	786,188 (23.4%)	65,034 (24.2%)	851,222 (23.4%)	0.02
Deprivation Quintile, n (%)	Missing	37,365 (1.1%)	2,063 (0.8%)	39,428 (1.1%)	0.04
	1	802,901 (23.9%)	45,106 (16.8%)	848,007 (23.4%)	0.18
	2	708,278 (21.1%)	47,637 (17.7%)	755,915 (20.8%)	0.08
	3	632,209 (18.8%)	52,504 (19.6%)	684,713 (18.9%)	0.02
	4	594,666 (17.7%)	55,590 (20.7%)	650,256 (17.9%)	0.08
	5	587,100 (17.5%)	65,621 (24.4%)	652,721 (18.0%)	0.17
Dependency Quintile, n (%)	Missing	37,365 (1.1%)	2,063 (0.8%)	39,428 (1.1%)	0.04
	1	901,394 (26.8%)	91,929 (34.2%)	993,323 (27.4%)	0.16
	2	671,373 (20.0%)	59,930 (22.3%)	731,303 (20.1%)	0.06
	3	582,059 (17.3%)	44,238 (16.5%)	626,297 (17.2%)	0.02
	4	557,097 (16.6%)	37,506 (14.0%)	594,603 (16.4%)	0.07
	5	613,231 (18.2%)	32,855 (12.2%)	646,086 (17.8%)	0.17
Ethnic Concentration Quintile, n (%)	Missing	37,365 (1.1%)	2,063 (0.8%)	39,428 (1.1%)	0.04
	1	535,172 (15.9%)	17,294 (6.4%)	552,466 (15.2%)	0.3
	2	579,980 (17.2%)	24,901 (9.3%)	604,881 (16.7%)	0.24
	3	635,538 (18.9%)	35,134 (13.1%)	670,672 (18.5%)	0.16
	4	726,900 (21.6%)	57,068 (21.3%)	783,968 (21.6%)	0.01
	5	847,564 (25.2%)	132,061 (49.2%)	979,625 (27.0%)	0.51
Rural, n (%)	Missing	8,780 (0.3%)	671 (0.2%)	9,451 (0.3%)	0
		339,985 (10.1%)	10,538 (3.9%)	350,523 (9.7%)	0.24
Pandemic Quarter	2020-Q1	19,479 (0.6%)	3,457 (1.3%)	22,936 (0.6%)	0.07
	2020-Q2	297,938 (8.9%)	21,179 (7.9%)	319,117 (8.8%)	0.04
	2020-Q3	686,688 (20.4%)	14,775 (5.5%)	701,463 (19.3%)	0.46
	2020-Q4	972,169 (28.9%)	104,177 (38.8%)	1,076,346 (29.6%)	0.21
	2021-Q1	1,386,245 (41.2%)	124,933 (46.5%)	1,511,178 (41.6%)	0.11
Received 2 vaccine doses, n (%)		71,870 (2.1%)	300 (0.1%)	72,170 (2.0%)	0.19
Received 1 vaccine dose, n (%)		78,444 (2.3%)	1,403 (0.5%)	79,847 (2.2%)	0.15
Received 0 vaccine doses, n (%)		3,212,205 (95.5%)	266,818 (99.4%)	3,479,023 (95.8%)	0.25

Aggregated diagnosis group	Mean ± SD	5.82 ± 3.80	5.59 ± 3.69	5.81 ± 3.79	0.06
	Median (IQR)	5 (3-8)	5 (3-8)	5 (3-8)	0.06
Hospital Frailty Risk Score	Mean ± SD	2.42 ± 4.76	2.40 ± 5.03	2.42 ± 4.78	0
	Median (IQR)	0 (0-3)	0 (0-2)	0 (0-3)	0.06
Hospitalizations in prior year	Mean ± SD	0.10 ± 0.45	0.07 ± 0.39	0.10 ± 0.44	0.07
	Median (IQR)	0 (0-0)	0 (0-0)	0 (0-0)	0.09
Clinic visits in prior year	Mean ± SD	6.56 ± 8.35	6.27 ± 7.86	6.54 ± 8.32	0.04
	Median (IQR)	4 (1-9)	4 (1-9)	4 (1-9)	0.03
Homecare visits in prior year	Mean ± SD	3.10 ± 25.71	2.92 ± 26.23	3.09 ± 25.75	0.01
	Median (IQR)	0 (0-0)	0 (0-0)	0 (0-0)	0.07
ED visits in prior year	Mean ± SD	0.50 ± 1.45	0.41 ± 1.42	0.49 ± 1.45	0.06
	Median (IQR)	0 (0-1)	0 (0-0)	0 (0-1)	0.08
Days hospitalized in prior year	Mean ± SD	1.02 ± 6.85	0.83 ± 7.88	1.00 ± 6.93	0.03
	Median (IQR)	0 (0-0)	0 (0-0)	0 (0-0)	0.15
Hospitalized within 2 weeks, n (%)		246,238 (7.3%)	14,942 (5.6%)	261,180 (7.2%)	0.07
Admitted to intensive care unit within 2 weeks, n (%)		31,068 (0.9%)	2,933 (1.1%)	34,001 (0.9%)	0.02
Johns Hopkins Frailty Index, n (%)		116,104 (3.5%)	7,895 (2.9%)	123,999 (3.4%)	0.03
Flu vaccine within prior year, n (%)		1,064,518 (31.7%)	66,351 (24.7%)	1,130,869 (31.1%)	0.15
Pregnancy, n (%)		29,558 (0.9%)	1,855 (0.7%)	31,413 (0.9%)	0.02
Hypertension, n (%)		816,144 (24.3%)	61,708 (23.0%)	877,852 (24.2%)	0.03
Diabetes, n (%)		395,575 (11.8%)	37,775 (14.1%)	433,350 (11.9%)	0.07
Emphysema, n (%)		93,686 (2.8%)	4,138 (1.5%)	97,824 (2.7%)	0.09
Heart failure, n (%)		88,669 (2.6%)	4,994 (1.9%)	93,663 (2.6%)	0.05
Dementia, n (%)		42,410 (1.3%)	3,274 (1.2%)	45,684 (1.3%)	0
Asthma, n (%)		414,612 (12.3%)	28,270 (10.5%)	442,882 (12.2%)	0.06
Cancer, n (%)		112,188 (3.3%)	4,809 (1.8%)	116,997 (3.2%)	0.1
Surgery in prior 6 weeks, n (%)		57,709 (1.7%)	2,215 (0.8%)	59,924 (1.7%)	0.08
Ischemic stroke, n (%)		42,908 (1.3%)	2,547 (0.9%)	45,455 (1.3%)	0.03
Hemorrhagic stroke, n (%)		3,533 (0.1%)	224 (0.1%)	3,757 (0.1%)	0.01
Valvular disease, n (%)		4,609 (0.1%)	235 (0.1%)	4,844 (0.1%)	0.01
Atrial fibrillation, n (%)		93,557 (2.8%)	4,896 (1.8%)	98,453 (2.7%)	0.06
Myocardial infarction, n (%)		33,446 (1.0%)	1,801 (0.7%)	35,247 (1.0%)	0.04
Percutaneous coronary intervention, n (%)		39,373 (1.2%)	2,231 (0.8%)	41,604 (1.1%)	0.03
Coronary artery bypass, n (%)		11,845 (0.4%)	648 (0.2%)	12,493 (0.3%)	0.02
Ischemic heart disease, n (%)		167,514 (5.0%)	9,846 (3.7%)	177,360 (4.9%)	0.06
Major bleeding, n (%)		37,210 (1.1%)	2,156 (0.8%)	39,366 (1.1%)	0.03
Renal disease, n (%)		43,949 (1.3%)	2,779 (1.0%)	46,728 (1.3%)	0.03
Pneumonia, n (%)		271,036 (8.1%)	20,166 (7.5%)	291,202 (8.0%)	0.02
Alcohol use disorder, n (%)		27,759 (0.8%)	1,668 (0.6%)	29,427 (0.8%)	0.02
Venous thromboembolism, n (%)		396,371 (11.8%)	24,085 (9.0%)	420,456 (11.6%)	0.09
Mental health hospitalization, n (%)		77,945 (2.3%)	4,470 (1.7%)	82,415 (2.3%)	0.05
Mental health emergency visit, n (%)		188,832 (5.6%)	11,469 (4.3%)	200,301 (5.5%)	0.06
Mental health clinic visit, n (%)		747,646 (22.2%)	48,712 (18.1%)	796,358 (21.9%)	0.1
Hospital mental health diagnoses, no. (%)					

Substance use disorder	19,681 (0.6%)	1,138 (0.4%)	20,819 (0.6%)	0.02
Dementia/Alzheimer's	2,034 (0.1%)	193 (0.1%)	2,227 (0.1%)	0
Delirium	5,696 (0.2%)	423 (0.2%)	6,119 (0.2%)	0
Anxiety	4,340 (0.1%)	203 (0.1%)	4,543 (0.1%)	0.02
Deliberate self-harm	5,492 (0.2%)	354 (0.1%)	5,846 (0.2%)	0.01
Schizophrenia	14,352 (0.4%)	937 (0.3%)	15,289 (0.4%)	0.01
Mood disorders	636 (0.0%)	23 (0.0%)	659 (0.0%)	0.01
Mood disorder - bipolar	8,380 (0.2%)	417 (0.2%)	8,797 (0.2%)	0.02
Mood disorder - depression	21,114 (0.6%)	1,015 (0.4%)	22,129 (0.6%)	0.04
Mood disorder - other	347 (0.0%)	12 (0.0%)	359 (0.0%)	0.01
Personality disorders	5,683 (0.2%)	234 (0.1%)	5,917 (0.2%)	0.02
Nonclassified	4,919 (0.1%)	302 (0.1%)	5,221 (0.1%)	0.01
Trauma/stress related disorders	9,008 (0.3%)	443 (0.2%)	9,451 (0.3%)	0.02
Obsessive compulsive disorder	465 (0.0%)	26 (0.0%)	491 (0.0%)	0
Eating disorder	854 (0.0%)	37 (0.0%)	891 (0.0%)	0.01
Emergency department mental health diagnoses, no. (%)				
Substance use disorder	60,371 (1.8%)	4,178 (1.6%)	64,549 (1.8%)	0.02
Dementia/Alzheimer's	1,971 (0.1%)	158 (0.1%)	2,129 (0.1%)	0
Delirium	1,195 (0.0%)	72 (0.0%)	1,267 (0.0%)	0
Anxiety	68,125 (2.0%)	3,872 (1.4%)	71,997 (2.0%)	0.04
Deliberate self-harm	16,222 (0.5%)	1,057 (0.4%)	17,279 (0.5%)	0.01
Schizophrenia	11,013 (0.3%)	745 (0.3%)	11,758 (0.3%)	0.01
Bipolar	5,640 (0.2%)	262 (0.1%)	5,902 (0.2%)	0.02
Depression	34,030 (1.0%)	1,778 (0.7%)	35,808 (1.0%)	0.04
Other	2,265 (0.1%)	108 (0.0%)	2,373 (0.1%)	0.01
Personality disorders	8,318 (0.2%)	446 (0.2%)	8,764 (0.2%)	0.02
Nonclassified	6,950 (0.2%)	473 (0.2%)	7,423 (0.2%)	0.01
Trauma/stress related disorders	41,958 (1.2%)	2,202 (0.8%)	44,160 (1.2%)	0.04
Obsessive compulsive disorder	626 (0.0%)	39 (0.0%)	665 (0.0%)	0
Eating disorder	614 (0.0%)	22 (0.0%)	636 (0.0%)	0.01
Outpatient OHIP mental health diagnosis codes, no. (%)				
Psychotic disorders	43,698 (1.3%)	3,137 (1.2%)	46,835 (1.3%)	0.01
Mood and anxiety disorders	385,325 (11.5%)	22,799 (8.5%)	408,124 (11.2%)	0.1
Substance use disorders	110,162 (3.3%)	6,198 (2.3%)	116,360 (3.2%)	0.06
Non-psychotic disorders	190,835 (5.7%)	12,795 (4.8%)	203,630 (5.6%)	0.04
Social problems	127,299 (3.8%)	8,967 (3.3%)	136,266 (3.8%)	0.02
Other	139,737 (4.2%)	9,465 (3.5%)	149,202 (4.1%)	0.03

Table E4: Distribution of baseline healthcare utilization rates (per person-year) for the matched cohort (n= 530,232), overall and stratified by sex.

Rate of baseline healthcare utilization (previous year; per person year)	SARS-CoV-2 PCR Test Result	Mean	std	Q1	Median	Q3	p95	p99
Overall								
Outpatient clinical encounters	Negative	6.3	7.9	1.0	4.0	8.0	21.0	37.0
	Positive	6.3	7.8	1.0	4.0	8.0	21.0	36.0
Homecare encounters	Negative	2.7	25.0	0.0	0.0	0.0	0.0	91.1
	Positive	2.8	25.7	0.0	0.0	0.0	0.0	95.1
Emergency department visits	Negative	0.4	1.2	0.0	0.0	0.0	2.0	4.0
	Positive	0.4	1.4	0.0	0.0	0.0	2.0	4.0
Days hospitalized	Negative	0.8	6.9	0.0	0.0	0.0	2.0	17.0
	Positive	0.8	7.3	0.0	0.0	0.0	2.0	17.0
Total healthcare utilization	Negative	10.2	29.5	1.0	4.0	10.0	29.0	131.1
	Positive	10.3	30.3	1.0	4.0	10.0	28.0	137.1
Women (n=271,346)								
Outpatient clinical encounters	Negative	7.2	8.3	2.0	5.0	10.0	23.0	38.0
	Positive	7.3	8.2	2.0	5.0	10.0	23.0	38.0
Homecare encounters	Negative	3.1	26.8	0.0	0.0	0.0	0.0	104.1
	Positive	3.5	29.4	0.0	0.0	0.0	0.0	132.1
Emergency department visits	Negative	0.4	1.1	0.0	0.0	0.0	2.0	4.0
	Positive	0.4	1.2	0.0	0.0	0.0	2.0	4.0
Days hospitalized	Negative	0.7	6.2	0.0	0.0	0.0	2.0	15.0
	Positive	0.8	6.4	0.0	0.0	0.0	2.0	16.0
Men (n=258,886)								
Outpatient clinical encounters	Negative	5.3	7.4	1.0	3.0	7.0	19.0	35.0
	Positive	5.2	7.4	1.0	3.0	7.0	18.0	34.0
Homecare encounters	Negative	2.4	22.8	0.0	0.0	0.0	0.0	68.0
	Positive	2.0	21.1	0.0	0.0	0.0	0.0	50.0
Emergency department visits	Negative	0.4	1.2	0.0	0.0	0.0	2.0	4.0
	Positive	0.4	1.5	0.0	0.0	0.0	2.0	4.0
Days hospitalized	Negative	0.9	7.6	0.0	0.0	0.0	2.0	20.0
	Positive	0.8	8.1	0.0	0.0	0.0	1.0	18.0

Table E5: Sensitivity analyses: (A) Follow-up begins after hospital discharge or 56 days, whichever occurred later, (B) follow-up censored on the date of entrance to long-term care, (C) follow-up censored at 6 months, and (D) matched by intensive care admission within two weeks after index date. All comparisons are for test-positive versus test-negative individuals. Distribution of follow-up time included for each analysis. Healthcare utilization rates reported per person-year. The difference in overall healthcare utilization rates between test-positive and negative individuals are reported for the mean, 95th percentile, and 99th percentile. Samples sizes as noted below.

Rates (per person-year)	SARS-CoV-2 Positive PCR Test Result	Mean	std	Δ for mean	Q1	Median	Q3	p95	p99	Δ for 95th percentile	Δ for 99th percentile
Sensitivity analysis (A): Follow-up ≥56 days (after hospital discharge) (n=530,232)											
Total healthcare utilization	Negative	12.8	40.5		1.2	4.5	10.7	34.5	264.4		
	Positive	14.2	45.1	1.3	1.4	4.9	11.3	36.4	335.4	1.8	71.0
Outpatient clinical encounters	Negative	7.1	10.6		0.0	4.0	9.5	24.7	45.1		
	Positive	7.4	11.2	0.3	1.0	4.4	10.1	25.2	45.0	0.6	-0.1
Homecare encounters	Negative	4.1	32.4		0.0	0.0	0.0	0.0	167.4		
	Positive	4.2	32.5	0.0	0.0	0.0	0.0	0.0	169.6	0.0	2.2
Emergency department visits	Negative	0.4	1.5		0.0	0.0	0.0	2.5	5.4		
	Positive	0.4	1.7	0.0	0.0	0.0	0.0	2.4	5.5	0.0	0.1
Days hospitalized	Negative	0.7	8.3		0.0	0.0	0.0	1.7	13.8		
	Positive	1.0	11.7	0.3	0.0	0.0	0.0	1.8	16.0	0.1	2.2
Days in long-term care	Negative	0.5	11.6		0.0	0.0	0.0	0.0	0.0		
	Positive	1.2	19.2	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Follow-up (days)	Negative	240	87		187	221	267	457	495		
	Positive	240	87		188	221	267	457	494		
Sensitivity analysis (B): Follow-up censored at entrance to long-term care (n=530,232)											
Rates (per person-year)		Mean	std	Δ for mean	Q1	Median	Q3	p95	p99	Δ for 95th percentile	Δ for 99th percentile
Total healthcare utilization	Negative	12.5	39.2		1.2	4.5	10.7	34.2	243.5		
	Positive	13.6	42.5	1.1	1.4	4.9	11.2	35.7	297.5	1.5	54.0
Outpatient clinical encounters	Negative	7.1	10.4		0.0	4.0	9.6	24.7	45.2		
	Positive	7.4	10.7	0.3	1.0	4.4	10.1	25.4	45.2	0.7	0.0
Homecare encounters	Negative	4.2	32.8		0.0	0.0	0.0	0.0	172.1		
	Positive	4.3	33.3	0.1	0.0	0.0	0.0	0.0	182.6	0.0	10.5
Emergency department visits	Negative	0.4	1.5		0.0	0.0	0.0	2.5	5.4		
	Positive	0.4	1.7	0.0	0.0	0.0	0.0	2.4	5.5	0.0	0.1
Days hospitalized	Negative	0.8	10.1		0.0	0.0	0.0	1.7	14.5		
	Positive	1.5	16.7	0.6	0.0	0.0	0.0	1.9	22.1	0.1	7.6
Days in long-term care	Negative		
	Positive		
Follow-up (days)	Negative	240	87		186	221	267	457	495		
	Positive	239	88		187	220	267	457	494		
Sensitivity analysis (C) Follow-up censored at 6 months (n=530,232)											
Rates (per person-year)		Mean	std	Δ for mean	Q1	Median	Q3	p95	p99	Δ for 95th percentile	Δ for 99th percentile
Total healthcare utilization	Negative	12.8	40.6		0.0	4.0	10.1	35.1	264.4		
	Positive	14.3	45.0	4.4	0.0	4.0	12.1	38.3	337.0	3.2	72.6
Outpatient clinical encounters	Negative	7.1	10.7		0.0	4.0	10.1	26.2	46.4		

Homecare encounters	Positive	7.5	11.0	0.3	0.0	4.0	10.1	26.2	46.4	0.0	0.0
	Negative	4.1	32.6		0.0	0.0	0.0	0.0	167.5		
Emergency department visits	Positive	4.1	32.5	-0.1	0.0	0.0	0.0	0.0	163.5	0.0	-4.0
	Negative	0.4	1.5		0.0	0.0	0.0	2.2	6.1		
Days hospitalized	Positive	0.4	1.7	0.2	0.0	0.0	0.0	2.1	6.1	0.0	0.0
	Negative	0.8	9.0		0.0	0.0	0.0	2.0	14.1		
Days in long-term care	Positive	1.3	13.7	4.7	0.0	0.0	0.0	2.0	22.2	0.0	8.1
	Negative	0.4	10.7		0.0	0.0	0.0	0.0	0.0		
Follow-up (days)	Positive	1.0	17.2	6.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	Negative	174	17		181	181	181	181	181		
	Positive	174	17		181	181	181	181	181		

Sensitivity analysis (D) Matched by intensive care unit admission within 2 weeks after index date (n=508,662)											
Rates (per person-year)		Mean	std	Δ for mean	Q1	Median	Q3	p95	p99	Δ for 95th percentile	Δ for 99th percentile
Total healthcare utilization	Negative	12.8	40.6		1.1	4.5	10.7	34.5	268.1		
	Positive	14.1	44.6	1.3	1.4	4.9	11.2	36.2	332.5	1.7	64.4
Outpatient clinical encounters	Negative	7.1	10.3		0.0	4.0	9.5	24.6	45.3		
	Positive	7.4	10.6	0.3	1.0	4.4	10.0	25.2	44.9	0.6	-0.4
Homecare encounters	Negative	4.1	32.4		0.0	0.0	0.0	0.0	163.5		
	Positive	4.1	32.0	0.0	0.0	0.0	0.0	0.0	161.4	0.0	-2.2
Emergency department visits	Negative	0.4	1.5		0.0	0.0	0.0	2.5	5.4		
	Positive	0.4	1.7	0.0	0.0	0.0	0.0	2.4	5.5	0.0	0.0
Days hospitalized	Negative	0.8	8.8		0.0	0.0	0.0	1.7	13.9		
	Positive	1.1	12.4	0.4	0.0	0.0	0.0	1.8	20.1	0.1	6.2
Days in long-term care	Negative	0.5	11.7		0.0	0.0	0.0	0.0	0.0		
	Positive	1.1	18.2	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0

